Single Technology Appraisals (STAs)
Baricitinib for treating moderate to severe rheumatoid arthritis [ID979].
Ponatinib for treating chronic myeloid leukaemia [ID671].
Ibrutinib for treating Waldenstrom’s macroglobulinaemia [ID884].
Ibrutinib for treating relapsed or refractory mantle cell lymphoma [ID753].
Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma [ID841].
Pertuzumab for treating early, HER 2 positive breast cancer [ID767].
Certolizumab pegol for treating rheumatoid arthritis following inadequate response to a TNF inhibitor [ID824].
Idiopathic pulmonary fibrosis - pirfenidone [ID837].
Adalimumab for treating moderate to severe hidradenitis suppurativa [ID812].
Cabazitaxel for the second-line treatment of hormone refractory, metastatic prostate cancer [ID889].
Olaparib for the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer with BRCA 1 or 2 mutations following response to prior platinum-based chemotherapy [ID735].
Hypercholesterolaemia (primary), dyslipidaemia (mixed) - evolocumab [ID765].
Vedolizumab for treating moderate to severe active Crohn’s disease after prior therapy [ID690].
Vedolizumab for ulcerative colitis [ID691].
Degarelix for the treatment of advanced hormone-dependent prostate cancer [ID590].
Sofosbuvir-ledipasvir for treating genotype 1 chronic hepatitis C [ID742].
Sipuleucel-T for the treatment of metastatic castrate-resistant prostate cancer [ID573].
Mepolizumab for treating severe eosinophilic asthma [ID798].
Lorcaserin for obesity [ID337].
Pegloticase for the treatment of hyperuricaemia in people with symptomatic gout whose disease is refractory to conventional urate-lowering therapy, or in whom conventional urate-lowering therapy is contraindicated or not tolerated [ID521] Report.
Bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer (08/211/01).
Trabectedin for the treatment of advanced metastatic soft tissue sarcoma (08/92/01).
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (08/03/01).
Febuxostat for the management of hyperuricaemia in people with gout (07/69/01).
Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (07/90/01).
Varenicline for smoking cessation (06/50/01).
Alteplase for the treatment of acute ischaemic stroke (06/51/01).
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal (05/53/01).
Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal (05/51/01).